The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, is a significant milestone for the company. It is the first gene therapy directly administered to the brain and ...
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...
GlobalData on MSN20h
FDA grants accelerated approval for PTC’s AADC deficiency gene therapyThe US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene ...
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
The gene therapy, which will be marketed in the United States with the brand name KEBILIDI (eladocagene exuparvovec-tneq), is indicated for the treatment of children and adults with AADC deficiency, ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback